Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02143635
Title	Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt
Recruitment	Completed
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	Novartis Pharmaceuticals
Indications	myelodysplastic/myeloproliferative neoplasm acute myeloid leukemia acute lymphoblastic leukemia Advanced Solid Tumor
Therapies	Siremadlin
Age Groups:	adult
Covered Countries	USA \| NLD \| FRA \| ESP \| DEU